Evidence map›Paper›PMID 41342046›Full record

ArticleKidney medicine2025

Associations of Podocyte-Derived Protein Biomarkers With Foot Process Effacement and Kidney Histopathologic Lesions in Individuals With Glomerular Disease.

Insa M Schmidt, Ashish Verma, Sophie Claudel, Sophia Rosan, Weining Lu, Laurence H Beck, Courtney Huynh, Ragnar Palsson, Anand Srivastava, Isaac Stillman and 9 more

Abstract read
In one paragraph

Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Insa M SchmidtSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Ashish VermaSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Sophie ClaudelSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Sophia RosanSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Weining LuSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Laurence H BeckSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Courtney HuynhSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.
Ragnar PalssonDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Anand SrivastavaDivision of Nephrology, University of Illinois Chicago, Chicago, IL.
Isaac StillmanDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.
Claire AvillachDepartment of Pathology, Massachusetts General Hospital, Boston, MA.
Tobias B HuberHamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jessica VolpeInternal Medicine Research Unit, Pfizer Inc, Cambridge, MA.
Carlos Morales BetanzosDrug Safety R&D, Pfizer Inc, Andover, MA.
Mireia Fernandez OcanaDrug Safety R&D, Pfizer Inc, Andover, MA.
Stephen P BerasiCenter for Therapeutic Innovation, Pfizer Inc, Cambridge, MA.
Kelly Alana FaderTranslational Clinical Sciences, Biomeasures, Endpoints and Study Technologies, Pfizer Inc, Cambridge, MA.
Mohamed HassaneinTranslational Clinical Sciences, Biomeasures, Endpoints and Study Technologies, Pfizer Inc, Cambridge, MA.
Sushrut S WaikarSection of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.

Funding

Molecular Pathogenesis of Vesicoureteral RefluxR01DK078226 · NIDDK · BOSTON MEDICAL CENTER · PI LU, WEINING · 2008 to 2018
$2.5M
New Therapeutic Leads for Proteinuric Kidney DiseasesR01DK133940 · NIDDK · BOSTON MEDICAL CENTER · PI LU, WEINING · 2022 to 2024
$790k
NIDDK NIH HHS R01 DK078226NIDDK NIH HHS R01 DK133940
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkersfoot process effacementglomerular diseasehistopathologykidney biopsyKidney diseasepodocyte injury

Identifiers

PMID41342046
PMCPMC12671356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.